Approval for donanemab, another antibody treatment, has been delayed after the FDA asked for more information on safety and efficacy. “These new antibody treatments [lecanemab and donanemab] ...
A new drug for Alzheimer’s disease is causing excitement despite excess deaths, missing safety data, questionable efficacy, and financial conflicts of interest among the “independent” advisory ...